United Therapeutics Corporation $UTHR Stake Raised by Profund Advisors LLC

Profund Advisors LLC raised its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 51.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,208 shares of the biotechnology company’s stock after buying an additional 1,776 shares during the quarter. Profund Advisors LLC’s holdings in United Therapeutics were worth $2,822,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in UTHR. Callan Family Office LLC purchased a new position in shares of United Therapeutics during the 2nd quarter valued at approximately $1,217,000. Andra AP fonden increased its stake in shares of United Therapeutics by 33.5% in the second quarter. Andra AP fonden now owns 34,904 shares of the biotechnology company’s stock worth $18,912,000 after buying an additional 8,760 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in United Therapeutics in the second quarter valued at $3,359,000. Partners Capital Investment Group LLP acquired a new stake in United Therapeutics in the second quarter valued at $1,691,000. Finally, Palo Alto Investors LP bought a new position in United Therapeutics during the 2nd quarter valued at $33,911,514. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In related news, CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $526.96, for a total value of $5,006,120.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $170,968,483.28. This trade represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 392,028 shares of company stock valued at $205,194,921 in the last three months. Insiders own 8.60% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on UTHR shares. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Royal Bank Of Canada decreased their price target on United Therapeutics from $708.00 to $697.00 and set an “outperform” rating for the company in a research note on Thursday, October 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $850.00 price objective on shares of United Therapeutics in a report on Monday, October 26th. Raymond James Financial restated an “outperform” rating and set a $717.00 price objective on shares of United Therapeutics in a research note on Tuesday, October 20th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $728.00 target price on shares of United Therapeutics in a report on Wednesday, October 14th. Twelve analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $667.07.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $598.72 on Monday. The stock has a market capitalization of $25.68 billion, a price-to-earnings ratio of 21.42, a price-to-earnings-growth ratio of 4.33 and a beta of 0.49. United Therapeutics Corporation has a 1-year low of $430.02 and a 1-year high of $609.99. The company’s fifty day moving average is $527.10 and its two-hundred day moving average is $530.54.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.41 EPS. Sell-side analysts expect that United Therapeutics Corporation will post 26.09 EPS for the current fiscal year.

United Therapeutics announced that its Board of Directors has authorized a stock buyback program on Thursday, October 22nd that authorizes the company to buy back $2 billion in shares. This repurchase authorization authorizes the biotechnology company to repurchase up to 8.3% of its shares through open market purchases. Share repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.